Background
==========

Diabetics often resort to herbal remedies as a 'natural' alternative to traditional medications in an effort to avoid adverse effects \[[@b1-amjcaserep-16-250]\]. Definitive efficacy and safety data on herbal medicines for diabetes are lacking. Nevertheless, the use of such treatments is on the rise, and clinicians are advised to ask and educate patients about their potential adverse effects \[[@b2-amjcaserep-16-250]\]. Cinnamon is considered to increase glucose uptake, glycogen synthesis, and phosphorylation of the insulin receptors \[[@b3-amjcaserep-16-250]\]. It has been shown to improve glycolated hemoglobin levels. While these studies demonstrate the efficacy of cinnamon on diabetes, they did not describe adverse effects caused by it. One of the contents of cinnamon is coumarin, which has associated health risks \[[@b4-amjcaserep-16-250]\]. A metabolite of coumarin could cause hepatotoxicity \[[@b5-amjcaserep-16-250]\], and its concomitant use with other medications that have potential for liver damage should be discouraged. Herein, we report a case of acute hepatitis after the addition of cinnamon to a high-dose regimen of rosuvastatin.

Case Report
===========

A 73-year-old woman was seen in the Emergency Department complaining of abdominal pain associated with vomiting and diarrhea after she started taking cinnamon supplements for about 1 week. The patient's pain was epigastric, radiating into her right upper quadrant and also into her chest. It was reported to be worse with palpation and deep inspiration, and was quite different from her angina pain, which necessitated her to have 2 stents placed approximately 8 months before this admission. The patient denied having any hematemesis, melena, or hematochezia. The patient's medical history included coronary artery disease with prior stent placement (8 months ago), hypertension, diabetes, depression, hyperlipidemia, gastroesophageal reflux, and chronic back pain. She also had a history of cholecystectomy, hysterectomy, and exploratory laparotomy for recurrent abdominal pain. She is a social alcohol drinker and current tobacco abuser. She was taking rosuvastatin 40 mg orally once a day for coronary artery disease. Her other medications included paroxetine, amlodipine, aspirin, clopidogrel, insulin, losartan, metoprolol, and pantoprazole. She had started taking a cinnamon supplement to treat her diabetes.

Physical examination revealed a blood pressure of 107/56 mm Hg, a heart rate of 74/min, a temperature of 99.1°F, respiratory rate of 18 breaths/min, and oxygen saturation of 95% on room air. Heart and lung examination results were essentially negative. Her abdomen was tender, with palpation more prominent in the epigastric region and right upper quadrant. She also had a positive Murphy's sign, but no scleral icterus. There were no signs of trauma to the abdomen and no ecchymoses or rashes. A complete laboratory workup is outlined in [Table 1](#t1-amjcaserep-16-250){ref-type="table"}, essentially consistent with acute hepatitis with cholestatic feature.

A CT scan of the abdomen showed mild biliary ductal dilatation greater than expected for post-cholecystectomy, but an obstructing mass or calculus was not identified. Abdominal ultrasound showed ductal dilation without obstructing mass or evidence of gross injury. A magnetic resonance cholangiopancreatography (MRCP) showed ductal dilation suspicious for dilation after previous cholecystectomy without an obstructive mass or calculus.

Rosuvastatin and the self-prescribed remedy of cinnamon were held. An endoscopic retrograde cholangiopancreatography (ERCP) was not performed because the patient had undergone drug-eluting stent placement approximately 8 months prior to admission and needed to continue dual antiplatelet therapy without interruption. As her hospital course progressed, her abdominal pain slowly resolved and she was discharged home. Since medication-induced hepatitis was higher in the differential diagnosis and the patient was on aspirin and clopidogrel, we decided to manage this patient conservatively. Therefore, liver biopsy was not performed. The statin therapy was restarted as an outpatient without resulting in elevated liver enzymes or abdominal pain ([Figure 1](#f1-amjcaserep-16-250){ref-type="fig"}).

Discussion
==========

The diagnosis of acute hepatitis covers a very broad spectrum of diagnoses. The common causes of significantly elevated liver enzymes are viral infection, toxins, and ischemia \[[@b6-amjcaserep-16-250]\]. In our patient, an elevated level of alkaline phosphatase and marked elevation of GGT suggests hepatobiliary etiologies. The imaging studies essentially ruled out biliary causes. Negative hepatitis viral panel excludes the diagnosis of viral-induced hepatitis. There was no evidence of trauma or hemodynamic compromise that could precipitate ischemic or traumatic hepatitis. Other rare causes of significant elevation of liver enzymes such as Budd-Chiari syndrome and autoimmune hepatitis were ruled out via detailed workup. There were no other medications the patient was taking that could cause the extent of liver damage, except the cinnamon supplement. [Table 2](#t2-amjcaserep-16-250){ref-type="table"} contains lists of diagnosis that could cause significantly elevated liver enzymes (greater than 15 times upper normal limits) \[[@b7-amjcaserep-16-250]\].

The combination of cinnamon supplementation and a high dose statin therapy was the likely etiology of the patient's acute hepatitis. It is possible that the high-dose Rosuvastatin (40 mg) may be an obvious culprit, but this occurs in the early course of therapy \[[@b8-amjcaserep-16-250]\]. Our patient had been taking rosuvastatin for months prior to the episode of acute hepatitis; therefore, it is unlikely the responsible agent. The overall risk of marked elevation of transaminases with statin is very small \[[@b9-amjcaserep-16-250]\]. Several studies have reported that the coumarin in cinnamon is associated with acute liver damage \[[@b10-amjcaserep-16-250],[@b11-amjcaserep-16-250]\]. Its concomitant use in patients taking statins is a concern \[[@b12-amjcaserep-16-250]\]. While the exact mechanism of hepatotoxic effect is not known, o-hydroxyphenylacetic acid (o-HPAA), a metabolite of coumarin, was found to be hepatotoxic in animal studies \[[@b5-amjcaserep-16-250]\]. Our patient had started taking cinnamon supplements along with a higher dose of rosuvastatin within a week of admission, and this combination may have caused an acute hepatitis-like syndrome with abdominal pain and significant liver enzyme elevation. This quickly resolved after the medications were held.

Naranjo et al. have devised a well-established algorithm to determine whether a medication is the cause of an adverse event or whether it is due to other confounding factors \[[@b13-amjcaserep-16-250]\]. When applying the Naranjo algorithm to the patient in question, the adverse drug reaction would be considered probable for this patient ([Table 3](#t3-amjcaserep-16-250){ref-type="table"}).

Conclusions
===========

Patients with coronary artery disease often have other conditions such as diabetes, and their medication regimen includes statin therapy. Our case report shows that the combination of cinnamon and statins has the potential for significant liver damage. Therefore, patients should be warned against the use of these medications in combination.
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###### 

The complete laboratory workup at the time of admission and discharge.

  **Laboratory Test**            **At Admission**   **At Discharge**   **Normal value**
  ------------------------------ ------------------ ------------------ ------------------
  Aspartate transaminase (AST)   927 units/L        52 units/L         10--35 units/L
  Alanine transaminase (ALT)     550 units/L        148 units/L        10--35 units/L
  Total Bilirubin                0.4 mg/dL          0.4 mg/dL          0.1--1.0 mg/dL
  Alkaline Phosphatase           245 units/L        144 units/L        35--129 units/L
  Creatinine                     0.6 mg/dL          0.6 mg/dL          0.5--1.0 mg/dL
  Gamma-glutamyl transferase     181 units/L        --                 0--40 units/L
  Albumin                        3.9 g/dL           4.1 g/dL           3.5--5.2 g/dL
  INR                            1.1                1.1                --
  Hemoglobin                     12.8 g/dL          13.1 g/dL          12--16 g/dL
  White blood cell count         2.9 g/dL           4.2 g/dL           4.8--10.8 g/dL
  Platelets                      158 K/mcl          158 K/mcl          150--400 K/mcl
  Total Protein                  5.8 g/dL           6.1 g/dL           6.6--8.7 g/dL
  Hepatitis A IgM Antibody       Negative           --                 Negative
  Hepatitis B surface Antigen    Negative           --                 Negative
  Hepatitis B surface Antibody   Negative           --                 Negative
  Hepatits B core IgM Antibody   Negative           --                 Negative
  Hepatitis C Antibody           Negative           --                 Negative
  ANA                            Negative           --                 Negative
  Anti--mitochondrial antibody   Negative           --                 Negative
  Anti--smooth muscle antibody   Negative           --                 Negative

###### 

Etiology of significantly elevated AST/ALT (\>15× upper normal limit).

  -----------------------------
  Acute viral hepatitis
  Medications and toxins
  Ischemic hepatitis
  Autoimmune hepatitis
  Wilson's disease
  Acute bile duct obstruction
  Budd-Chiari syndrome
  Hepatic artery ligation
  -----------------------------

###### 

The Naranjo Adverse Drug Reaction (ADR) Probability Scale for our patient.

  **Questions**                                                                                                    **Yes**   **No**   **Do not know**   **Our patient**
  ---------------------------------------------------------------------------------------------------------------- --------- -------- ----------------- -----------------
  1\. Are there previous conclusive reports on this reaction?                                                      +1        0        0                 +1
  2\. Did the adverse event appear after the suspected drug was administered?                                      +2        −1       0                 +2
  3\. Did the adverse reaction improve when the drug was discontinued or a specific antagonist was administered?   +1        0        0                 +1
  4\. Did the adverse reaction reappear when the drug was re-administered?                                         +2        −1       0                 0
  5\. Are there alternative causes (other than the drug) that could on their own have caused the reaction?         −1        +2       0                 0
  6\. Did the reaction reappear when a placebo was given?                                                          −1        +1       0                 0
  7\. Was the drug detected in the blood (or other fluids) in concentrations known to be toxic?                    +1        0        0                 0
  8\. Was the reaction more severe when the dose was increased, or less severe when the dose was decreased?        +1        0        0                 +1
  9\. Did the patient have a similar reaction to the same or similar drugs in any previous exposure?               +1        0        0                 0
  10\. Was the adverse event confirmed by any objective evidence?                                                  +1        0        0                 +1
  **Cumulative score**                                                                                                                                  +6

Score of: 0=doubtful ADR, 1--4=possible ADR, 5--8=probable ADR, greater than 9=definitive
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